We started 2026 with a strong business performance driven by the continued launch success of Altuvoct and Gamifant. Additionally, we made significant advances with our pipeline with the launch of Aspaveli in C3G and IC-MPGN, and the filing of Tryngolza in sHTG in Europe.

We have delivered significant results in the business in 2025 and importantly made tremendous progress with our pipeline setting Sobi up for significant longer term growth potential. We look forward with excitement to bringing these medicines to more and more people in need of innovative treatments.

We delivered strong quarterly results and achieved 16 per cent revenue growth at CER demonstrating the strength of our portfolio. In 2025, we made significant advances with our pipeline, highlighted by the regulatory submissions of Aspaveli, and NASP, the pivotal read out of Tryngolza in sHTG and the agreement to acquire Arthrosi Therapeutics in order to strengthen our gout franchise.

For the quarter, our business accelerated and achieved 21 per cent growth at CER demonstrating the strength of our portfolio. We also advanced our pipeline with the US filing acceptance for NASP in uncontrolled gout and the preparations for a new opportunity for olezarsen in severe hypertriglyceridemia, both expected to contribute significantly to long-term growth.